Merck and Eisai to stop Keytruda plus Lenvima trial in head and neck cancer after disappointing interim results
Merck and Eisai announced Friday morning that they plan to close a Phase III study of the combination of Keytruda and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.